CA Patent

CA2696579A1 — Purine derivatives for use in the treatment of fab-related diseases

Assigned to Boehringer Ingelheim International GmbH · Expires 2009-02-26 · 17y expired

What this patent protects

The specification describes the use of selected purine derivatives for the treatment of hyperproliferative diseases.

USPTO Abstract

The specification describes the use of selected purine derivatives for the treatment of hyperproliferative diseases.

Drugs covered by this patent

Patent Metadata

Patent number
CA2696579A1
Jurisdiction
CA
Classification
—
Expires
2009-02-26
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.